1
|
Dannehl D, Jakob D, Mergel F, Estler A, Engler T, Volmer L, Frevert ML, Matovina S, Englisch A, Tegeler CM, Rohner A, Seller A, Hahn M, Pfister K, Fink A, Popp I, Lorenz S, Tabatabai G, Juhasz-Böss I, Janni W, Brucker S, Taran FA, Hartkopf A, Schäffler H. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis. ESMO Open 2024; 9:102995. [PMID: 38636292 PMCID: PMC11039313 DOI: 10.1016/j.esmoop.2024.102995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 02/22/2024] [Accepted: 03/11/2024] [Indexed: 04/20/2024] Open
Abstract
BACKGROUND Fifteen to thirty percent of all patients with metastatic breast cancer (MBC) develop brain metastases (BCBMs). Recently, the antibody-drug conjugates (ADCs) sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have shown to be highly effective in the treatment of MBC. However, there are only limited data whether these macromolecules are also effective in patients with BCBMs. We therefore aimed to examine the efficacy of SG and T-DXd in patients with stable and active BCBMs in a multicenter real-world analysis. PATIENTS AND METHODS Female patients with stable or active BCBMs who were treated with either SG or T-DXd at three breast centers in Germany before 30 June 2023 were included. As per local clinical praxis, chemotherapy efficacy was evaluated by whole-body computed tomography and cranial magnetic resonance imaging at baseline and at least every 3 months according to local standards. Growth dynamics of BCBMs were assessed by board-certified neuroradiologists. RESULTS Of 26 patients, with a median of 2.5 prior therapy lines in the metastatic setting (range 2-15), 12 (43%) and 16 (57%) patients received SG and T-DXd, respectively. Out of the 12 patients who received SG, 2 (17%) were subsequently treated with T-DXd. Five out of 12 (42%) and 5 out of 16 (31%) patients treated with SG and T-DXd, respectively, had active BCBMs at treatment initiation. The intracranial disease control rate was 42% [95% confidence interval (CI) 13% to 71%] for patients treated with SG and 88% (95% CI 72% to 100%) for patients treated with T-DXd. After a median follow-up of 12.7 months, median intracranial progression-free survival was 2.7 months (95% CI 1.6-10.5 months) for SG and 11.2 months (95% CI 7.5-23.7 months) for T-DXd. CONCLUSIONS SG and T-DXd showed promising clinical activity in both stable and active BCBMs. Further prospective clinical studies designed to investigate the efficacy of modern ADCs on active and stable BCBMs are urgently needed.
Collapse
Affiliation(s)
- D Dannehl
- Department of Women's Health, Tuebingen University, Tuebingen.
| | - D Jakob
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg
| | - F Mergel
- Department of Gynecology and Obstetrics, Ulm University, Ulm
| | - A Estler
- Department of Radiology, Section for Diagnostic and Interventional Neuroradiology, Tuebingen
| | - T Engler
- Department of Women's Health, Tuebingen University, Tuebingen
| | - L Volmer
- Department of Women's Health, Tuebingen University, Tuebingen
| | - M-L Frevert
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg
| | - S Matovina
- Department of Women's Health, Tuebingen University, Tuebingen
| | - A Englisch
- Department of Women's Health, Tuebingen University, Tuebingen
| | - C M Tegeler
- Department of Women's Health, Tuebingen University, Tuebingen
| | - A Rohner
- Department of Women's Health, Tuebingen University, Tuebingen
| | - A Seller
- Department of Women's Health, Tuebingen University, Tuebingen
| | - M Hahn
- Department of Women's Health, Tuebingen University, Tuebingen
| | - K Pfister
- Department of Gynecology and Obstetrics, Ulm University, Ulm
| | - A Fink
- Department of Gynecology and Obstetrics, Ulm University, Ulm
| | - I Popp
- Department of Radiation Oncology, University Medical Center Freiburg, Freiburg
| | - S Lorenz
- Department of Radiology, Ulm University, Ulm
| | - G Tabatabai
- Center for Neurooncology, Comprehensive Cancer Center, Tuebingen University, Tuebingen, Germany
| | - I Juhasz-Böss
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg
| | - W Janni
- Department of Gynecology and Obstetrics, Ulm University, Ulm
| | - S Brucker
- Department of Women's Health, Tuebingen University, Tuebingen
| | - F-A Taran
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg
| | - A Hartkopf
- Department of Women's Health, Tuebingen University, Tuebingen; Department of Gynecology and Obstetrics, Ulm University, Ulm
| | - H Schäffler
- Department of Gynecology and Obstetrics, Ulm University, Ulm
| |
Collapse
|
2
|
Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F, Hayashi N, Sohn J, Teixeira de Sousa R, Brufsky AM, O'Brien CS, Schmitt F, Higgins G, Varghese D, James GD, Moh A, Livingston A, de Giorgio-Miller V. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. ESMO Open 2023; 8:101615. [PMID: 37562195 PMCID: PMC10515285 DOI: 10.1016/j.esmoop.2023.101615] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 07/05/2023] [Accepted: 07/08/2023] [Indexed: 08/12/2023] Open
Abstract
BACKGROUND Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth factor receptor 2 (HER2)-negative [immunohistochemistry (IHC) 0, 1+, or 2+/in situ hybridization (ISH) negative]; approximately 60% of BCs traditionally categorized as HER2-negative express low levels of HER2. HER2-low (IHC 1+ or IHC 2+/ISH-) status became clinically actionable with approval of trastuzumab deruxtecan to treat unresectable/metastatic HER2-low BC. Greater understanding of patients with HER2-low disease is urgently needed. PATIENTS AND METHODS This global, multicenter, retrospective study (NCT04807595) included tissue samples from patients with confirmed HER2-negative unresectable/metastatic BC [any hormone receptor (HR) status] diagnosed from 2014 to 2017. Pathologists rescored HER2 IHC-stained slides as HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2 IHC 0 after training on low-end expression scoring using Ventana 4B5 and other assays at local laboratories (13 sites; 10 countries) blinded to historical scores. HER2-low prevalence and concordance between historical scores and rescores were assessed. Demographics, clinicopathological characteristics, treatments, and outcomes were examined. RESULTS In rescored samples from 789 patients with HER2-negative unresectable/metastatic BC, the overall HER2-low prevalence was 67.2% (HR positive, 71.1%; HR negative, 52.8%). Concordance was moderate between historical and rescored HER2 statuses (81.3%; κ = 0.583); positive agreement was numerically higher for HER2-low (87.5%) than HER2 IHC 0 (69.9%). More than 30% of historical IHC 0 cases were rescored as HER2-low overall (all assays) and using Ventana 4B5. There were no notable differences between HER2-low and HER2 IHC 0 in patient characteristics, treatments received, or clinical outcomes. CONCLUSIONS Approximately two-thirds of patients with historically HER2-negative unresectable/metastatic BC may benefit from HER2-low-directed treatments. Our data suggest that HER2 reassessment in patients with historical IHC 0 scores may be considered to help optimize selection of patients for treatment. Further, accurate identification of patients with HER2-low BC may be achieved with standardized pathologist training.
Collapse
Affiliation(s)
- G Viale
- Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.
| | - M Basik
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada
| | - N Niikura
- Tokai University School of Medicine, Isehara, Kanagawa Prefecture, Japan
| | - E Tokunaga
- National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka Prefecture, Japan
| | - S Brucker
- Research Institute for Women's Health, University of Tübingen, Tübingen, Germany
| | - F Penault-Llorca
- Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, France
| | - N Hayashi
- St Luke's International Hospital, Tokyo, Tokyo Prefecture, Japan
| | - J Sohn
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
| | | | - A M Brufsky
- University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh, USA
| | - C S O'Brien
- The Christie NHS Foundation Trust, Manchester, UK
| | - F Schmitt
- Medical Faculty of the University of Porto, CINTESIS@RISE (Health Research Network), Molecular Pathology Unit, Ipatimup, Porto, Portugal
| | - G Higgins
- Victorian Cancer Biobank, Melbourne, Australia
| | - D Varghese
- Epidemiology, Global Real World Evidence Generation, OBU Medical, AstraZeneca, Gaithersburg, USA
| | - G D James
- Medical Statistics Consultancy Ltd, London, UK
| | - A Moh
- Daiichi Sankyo, Inc., Basking Ridge, USA
| | - A Livingston
- Global Medical Affairs, Medical Breast, OBU Medical, AstraZeneca, City House, Cambridge, UK
| | - V de Giorgio-Miller
- Global Medical Affairs, Medical Breast, OBU Medical, AstraZeneca, City House, Cambridge, UK
| |
Collapse
|
3
|
Dannehl D, Dijkstra T, Gutsfeld R, Au AV, Volmer L, Engler T, Hahn M, Hawighorst-Knapstein S, Chaudhuri A, Wallwiener M, Bauer A, Brucker S, Wallwiener S, Hartkopf A. P010 Retrospective modeling of adherence to endocrine therapy in early breast cancer using real-world claims data. Breast 2023. [DOI: 10.1016/s0960-9776(23)00129-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
4
|
Rall KK, Schöller D, Kölle A, Brucker S. Fehlbildungen des weiblichen Genitales und operative Therapie. Gynäkologische Endokrinologie 2021. [DOI: 10.1007/s10304-020-00364-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Drechsel-Grau A, Krämer B, Kommoss S, Grube M, Goth M, Brucker S, Andress J. Tief infiltrierende Endometriose (TIE): Evaluation postoperativer klinischer Verläufe an der Universitätsfrauenklinik Tübingen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Drechsel-Grau
- Universitätsklinikum Tübingen, Department für Frauengesundheit
| | - B Krämer
- Universitätsklinikum Tübingen, Department für Frauengesundheit
| | - S Kommoss
- Universitätsklinikum Tübingen, Department für Frauengesundheit
| | - M Grube
- Universitätsklinikum Tübingen, Department für Frauengesundheit
| | - M Goth
- Universitätsklinikum Tübingen, Department für Frauengesundheit
| | - S Brucker
- Universitätsklinikum Tübingen, Department für Frauengesundheit
| | - J Andress
- Universitätsklinikum Tübingen, Department für Frauengesundheit
| |
Collapse
|
6
|
Neis F, Brucker S, Hübner M. Veränderung der Hysterektomie-Zahlen in Deutschland in den Jahren 2010, 2015 und 2018. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- F. Neis
- Department für Frauengesundheit der Universität Tübingen
| | - S. Brucker
- Department für Frauengesundheit der Universität Tübingen
| | | |
Collapse
|
7
|
Anderle N, Ruoff F, Koch A, Hartkopf A, Brucker S, Templin M, Schmees C. Project PRIMO – Combining Patient Derived Breast Cancer Microtumors and DigiWest protein signaling pathway profiling for therapeutic response prediction. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30721-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
8
|
Krämer B, Kommoss S, Hoffmann S, Brucker S, Andress J, Neis F, Höller A. Eine prospektive, randomisierte, kontrollierte klinische Studie zur Adhäsionsprophylaxe nach Resektion von Endometriose mit 4DryField® PH. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- B Krämer
- Universitäts-Frauenklinik Tübingen
| | | | | | | | | | - F Neis
- Universitäts-Frauenklinik Tübingen
| | - A Höller
- Universitäts-Frauenklinik Tübingen
| |
Collapse
|
9
|
Feil L, Senz J, Ta M, Huvila J, Greif K, Krämer B, Brucker S, Grimm C, Bartl T, Zeder-Gösz C, Schmöckel E, Trillsch F, Mahner S, Kommoss F, Lehr HA, Wiedemeyer K, Köbel M, Staebler A, Anglesio M, Kommoss S. Molecular stratification of clear cell ovarian carcinomas. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | - J Senz
- University of British Columbia, OVCARE/Dep. of Obstetrics and Gynecology
| | - M Ta
- University of British Columbia, OVCARE/Dep. of Obstetrics and Gynecology
| | - J Huvila
- University of British Columbia, OVCARE/Dep. of Obstetrics and Gynecology
| | - K Greif
- Institut für Pathologie und Neuropathologie, Abteilung Allgemeine Pathologie und Pathologische Anatomie
| | | | | | - C Grimm
- Universitätsklinik für Frauenheilkunde, Abteilung für allgemeine Gynäkologie und gynäkologische Onkologie
| | - T Bartl
- Universitätsklinik für Frauenheilkunde, Abteilung für allgemeine Gynäkologie und gynäkologische Onkologie
| | - C Zeder-Gösz
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - E Schmöckel
- Pathologisches Institut der Ludwig-Maximilians-Universität
| | - F Trillsch
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - F Kommoss
- Institut für Pathologie im Medizin Campus Bodensee
| | - H.-A Lehr
- Institut für Pathologie im Medizin Campus Bodensee
| | - K Wiedemeyer
- Department of Pathology and Laboratory Medicine, University of Calgary
| | - M Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary
| | - A Staebler
- Institut für Pathologie und Neuropathologie, Abteilung Allgemeine Pathologie und Pathologische Anatomie
| | - M Anglesio
- University of British Columbia, OVCARE/Dep. of Obstetrics and Gynecology
| | | |
Collapse
|
10
|
Wandel L, Abele H, Brucker S, Rall K. Auswertung prä- und peripartaler Faktoren bei Mehrlingsgraviditäten an einem Perinatalzentrum Level 1 und Verlauf seit 2004. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Wandel
- Uni-Frauenklinik, Department für Frauengesundheit
| | - H Abele
- Uni-Frauenklinik, Department für Frauengesundheit
| | - S Brucker
- Uni-Frauenklinik, Department für Frauengesundheit
| | - K Rall
- Uni-Frauenklinik, Department für Frauengesundheit
| |
Collapse
|
11
|
Volmer L, Engler T, Staebler A, Hahn M, Kommoss S, Krämer B, Brucker S, Hartkopf A. Erstmanifestation eines Muir-Torre-Syndroms. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Volmer
- Universitätsfrauenklinik Tübingen
| | - T Engler
- Universitätsfrauenklinik Tübingen
| | | | - M Hahn
- Universitätsfrauenklinik Tübingen
| | | | - B Krämer
- Universitätsfrauenklinik Tübingen
| | | | | |
Collapse
|
12
|
Henes M, Bösmüller H, Neis F, Wallwiener D, Brucker S, Weiss M. Non-invasive-physical-plasma treatment of low- and high-grade cervical intraepithelial neoplasia: a non-invasive and anaesthesia-independent treatment procedure evaluated in a prospective, monocentric clinical trial. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | | | | | | | | | - M Weiss
- Natural and Medical Sciences Institute (NMI) at the University of Tübingen
| |
Collapse
|
13
|
Heitz F, Krämer P, Talhouk A, MA B, DS C, ES C, Scheunhage D, RF H, Senz J, Leung S, Hartkopf A, Krämer B, Brucker S, du Bois A, Harter P, FK K, Heublein S, Kommoss F, JN M, Singh N, Bosse T, Köbel M, MS A, Staebler A, Kommoss S. Anwendung der molekularen Risikostratifikation des Endometriums auf das endometrioide Ovarialkarzinom- eine retrospektive, internationale Multizenterstudie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- F Heitz
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - P Krämer
- Tuebingen University Hospital, Department of Women’s Health
- University of British Columbia, Department of Obstetrics and Gynecology
| | - A Talhouk
- University of British Columbia, Department of Obstetrics and Gynecology
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
| | - Brett MA
- McMaster University, Department of Pathology and Molecular Medicine
| | - Chiu DS
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
- BC Cancer Research Centre, Department of Molecular Oncology
| | - Cairns ES
- University of British Columbia, Department of Obstetrics and Gynecology
| | - D Scheunhage
- Leiden University Medical Centre (LUMC), Department of Pathology
| | - Hammond RF
- Barts Health National Health Service Trust, Department of Pathology
| | - J Senz
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
- University of British Columbia, Department of Pathology and Laboratory Medicine
| | - S Leung
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
- University of British Columbia, Department of Pathology and Laboratory Medicine
| | - A Hartkopf
- Tuebingen University Hospital, Department of Women’s Health
| | - B Krämer
- Tuebingen University Hospital, Department of Women’s Health
| | - S Brucker
- Tuebingen University Hospital, Department of Women’s Health
| | - A du Bois
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - P Harter
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - Kommoss FK
- Heidelberg University Hospital, Institute of Pathology
| | - S Heublein
- Heidelberg University Hospital, Heidelberg and National Center for Tumor Diseases, Department of Obstetrics and Gynecology
| | - F Kommoss
- Medizin Campus Bodensee, Institute of Pathology
| | - McAlpine JN
- University of British Columbia, Department of Obstetrics and Gynecology
- BC Cancer Research Centre, Department of Molecular Oncology
| | - N Singh
- Barts Health National Health Service Trust, Department of Pathology
| | - T Bosse
- Leiden University Medical Centre (LUMC), Department of Pathology
| | - M Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary
| | - Anglesio MS
- University of British Columbia, Department of Obstetrics and Gynecology
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
| | - A Staebler
- University Hospital Tuebingen, Institute of Pathology and Neuropathology
| | - S Kommoss
- Tuebingen University Hospital, Department of Women’s Health
| |
Collapse
|
14
|
Haßdenteufel K, Hawighort-Knapstein S, Götz M, Joos S, Wallwiener D, Brucker S, Colombo M, Wallwiener M, Wallwiener S. Real-World Data „Frauengesundheit und Präventionsmedizin“ als Kooperationsprojekt mit der AOK Baden-Württemberg. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | | | - M. Götz
- Universitätsfrauenklinik Heidelberg
| | - S. Joos
- Institut für Allgemeinmedizin und Interprofessionelle Versorgung
| | | | | | - M. Colombo
- Institut für Allgemeinmedizin und Interprofessionelle Versorgung
| | | | | |
Collapse
|
15
|
Peuker CA, Yaghobramzi S, Lüftner D, Brucker S, Decker T, Fasching P, Fehm T, Janni W, Kümmel S, Schneeweiss A, Schuler M, Busse A. Einfluss des CDK4/6-Inhibitors Ribociclib auf die periphere Immunantwort beim Hormonrezeptor-positiven Mammakarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1714608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
Affiliation(s)
- CA Peuker
- Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie, Onkologie und Tumorimmunologie
| | - S Yaghobramzi
- Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie, Onkologie und Tumorimmunologie
| | - D Lüftner
- Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie, Onkologie und Tumorimmunologie
| | | | - T Decker
- Gemeinschaftspraxis Onkologie Ravensburg
| | - P Fasching
- Frauenklinik, Universitätsklinikum Erlangen
| | - T Fehm
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Düsseldorf
| | - W Janni
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm
| | - S Kümmel
- Klinik für Senologie/Interdisziplinäres Brustkrebszentrum, Kliniken Essen-Mitte
| | - A Schneeweiss
- Klinik für Frauenheilkunde und Geburtshilfe, Universität Heidelberg
| | - M Schuler
- Klinik für Medizinische Onkologie, Universitätsklinikum Essen
| | - A Busse
- Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie, Onkologie und Tumorimmunologie
| |
Collapse
|
16
|
de Placido S, Brucker S, Law E, Ajmera M, Mitra D, Davis K, Harbeck N, De Laurentiis M. 175P Real-world patient and practice characteristics associated with use of CDK4/6 inhibitors among patients receiving first therapy for HR+/HER2- advanced or metastatic breast cancer in Italy and Germany. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
17
|
Graf J, Mauel L, Wallwiener M, Brucker S, Wallwiener S. Mind : Pregnancy – Ein systematisches Screening- und achtsamkeitsbasiertes Behandlungsprogramm zur Förderung der psychischen Gesundheit von Schwangeren. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0039-3402972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Affiliation(s)
- J Graf
- Psychosomatische Medizin und Psychotherapie, Universitätsklinikum Tübingen
| | - L Mauel
- Psychosomatische Medizin und Psychotherapie, Universitätsklinikum Tübingen
| | | | - S Brucker
- Frauenklinik, Universitätsklinikum Tübingen
| | | |
Collapse
|
18
|
Brucker S, Law E, Ajmera M, Mitra D, Davis K, Harbeck N, De Laurentiis M. Gastrointestinal symptoms & health-related quality of life among women with HR+/HER2– advanced or metastatic breast cancer treated in real-world settings in Italy and Germany. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz100.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
19
|
Harbeck N, Law E, Ajmera M, Mitra D, Davis K, Brucker S, De Laurentiis M. Prevalence of risk factors for QT prolongation and torsades de pointes among women with HR+/HER2– advanced or metastatic breast cancer treated in real-world settings in Italy and Germany. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz100.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
De Colle C, Weidner N, Heinrich V, Brucker S, Hahn M, MacMillan K, Lamprecht U, Gaupp S, Voigt O, Zips D. EP-1317 Hyperthermic chest wall re-irradiation in recurrent breast cancer: a prospective observational study. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31737-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
Kagan KO, Enders M, Schampera MS, Baeumel E, Hoopmann M, Geipel A, Berg C, Goelz R, De Catte L, Wallwiener D, Brucker S, Adler SP, Jahn G, Hamprecht K. Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration. Ultrasound Obstet Gynecol 2019; 53:383-389. [PMID: 29947159 DOI: 10.1002/uog.19164] [Citation(s) in RCA: 81] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Revised: 06/11/2018] [Accepted: 06/14/2018] [Indexed: 06/08/2023]
Abstract
OBJECTIVE To examine the efficacy of biweekly hyperimmunoglobulin (HIG) administration to prevent maternal-fetal transmission of cytomegalovirus (CMV) in women with primary first-trimester CMV infection. METHODS This was a prospective observational study of women with confirmed primary CMV infection in the first trimester who had the first HIG administration at or before 14 weeks' gestation. All women had biweekly HIG treatment until 20 weeks' gestation at a dose of 200 IU/kg of maternal body weight. Each subject underwent amniocentesis at least 6 weeks after first presentation at about 20 weeks. Primary outcome was maternal-fetal transmission at the time of amniocentesis, and secondary outcome was the frequency of congenital CMV infection at birth. The results were compared with a historic cohort of women with first-trimester CMV infection who did not undergo HIG treatment and who had amniocentesis at about 20 weeks. RESULTS Subjects were 40 pregnant women with a primary CMV infection, with a median gestational age at first presentation of 9.6 (range, 5.1-14.3) weeks. On average, HIG administration started at 11.1 weeks and continued until 16.6 weeks. Within this interval, HIG was administered between two and six times in each patient. While CMV immunoglobulin-G (IgG) monitoring showed periodic fluctuations during biweekly HIG administration cycles, high CMV-IgG avidity indices remained stable over the whole treatment period. Maternal-fetal transmission before amniocentesis occurred in only one of the 40 cases (2.5% (95% CI, 0-13.2%)). At delivery, two additional subjects were found to have had late-gestation transmission. Considering all three cases with maternal-fetal transmission, the transmission rate was 7.5% (95% CI, 1.6-20.4%) in our 40 cases. All infected neonates were asymptomatic at birth. The matched historical control group consisted of 108 pregnancies. Thirty-eight transmissions (35.2% (95% CI, 26.2-45.0%)) occurred in the control group, which was significantly higher (P < 0.0001) than the transmission rate in the HIG treatment group. CONCLUSION After a primary maternal CMV infection in the first trimester, biweekly HIG administration at a dose of 200 IU/kg prevents maternal-fetal transmission up to 20 weeks' gestation. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- K O Kagan
- Department of Women's Health, University of Tübingen, Tübingen, Germany
| | - M Enders
- Laboratory Prof. Gisela Enders & Colleagues MVZ and Institute of Virology, Infectiology and Epidemiology e.V, Stuttgart, Germany
| | - M S Schampera
- Institute of Medical Virology and Epidemiology of Viral Diseases, University of Tübingen, Tübingen, Germany
| | - E Baeumel
- Institute of Medical Virology and Epidemiology of Viral Diseases, University of Tübingen, Tübingen, Germany
| | - M Hoopmann
- Department of Women's Health, University of Tübingen, Tübingen, Germany
| | - A Geipel
- Department of Obstetrics and Gynaecology, University of Bonn, Bonn, Germany
| | - C Berg
- Department of Obstetrics and Gynaecology, University of Cologne, Cologne, Germany
| | - R Goelz
- Department of Neonatology, University of Tübingen, Tübingen, Germany
| | - L De Catte
- Department of Obstetrics and Gynaecology, University of Leuven, Leuven, Belgium
| | - D Wallwiener
- Department of Women's Health, University of Tübingen, Tübingen, Germany
| | - S Brucker
- Department of Women's Health, University of Tübingen, Tübingen, Germany
| | - S P Adler
- CMV Research Foundation, Richmond, VA, USA
| | - G Jahn
- Institute of Medical Virology and Epidemiology of Viral Diseases, University of Tübingen, Tübingen, Germany
| | - K Hamprecht
- Institute of Medical Virology and Epidemiology of Viral Diseases, University of Tübingen, Tübingen, Germany
| |
Collapse
|
22
|
Neven P, Petrakova K, Bianchi G, De La Cruz Merino L, Jerusalem G, Beck J, Sonke G, Chia S, Brucker S, Wang Y, He W, Rodriguez Lorenc K, Su F, Im SA. Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.336] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
De Laurentiis M, König A, Davis K, Mitra D, Nuzzo C, Ajmera M, de Placido S, Brucker S, Harbeck N. Health related quality of life in women with HR+/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.324] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Kagan KO, Sroka F, Sonek J, Abele H, Lüthgens K, Schmid M, Wagner P, Brucker S, Wallwiener D, Hoopmann M. First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial. Ultrasound Obstet Gynecol 2018; 51:437-444. [PMID: 28925570 DOI: 10.1002/uog.18905] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Revised: 09/01/2017] [Accepted: 09/07/2017] [Indexed: 06/07/2023]
Abstract
OBJECTIVE This was a randomized controlled trial to compare risk assessment by first-trimester combined screening (FTCS) with an approach that combines a detailed ultrasound examination at 11-13 weeks' gestation and cell-free DNA (cfDNA) analysis. METHODS Pregnant women with a normal first-trimester ultrasound examination at 11-13 weeks' gestation (fetal nuchal translucency (NT) ≤ 3.5 mm and no fetal defects) were randomized into one of two groups. In the first group, risk of aneuploidy was assessed using FTCS based on the most recent UK Fetal Medicine Foundation algorithm. In the second group, risk assessment was based on ultrasound findings and cfDNA analysis. An additional tube of blood was collected for FTCS in case the cfDNA analysis was uninformative. Primary outcome was false-positive rate in screening for trisomy 21. A case was considered false positive if the karyotype was not trisomy 21 and if the risk for trisomy 21 was >1:100, irrespective of the method of risk calculation. Results were compared using 95% CIs using the Clopper-Pearson method. RESULTS Between October 2015 and December 2016, 1518 women with singleton pregnancy underwent first-trimester screening. Thirty-one (2.0%) pregnancies were not eligible for randomization due to increased NT (> 3.5 mm) and/or fetal defect. After exclusion of women who declined randomization (n = 87) and cases of fetal death and loss to follow-up (n = 24), 688 pregnancies were randomized into the FTCS arm and 688 into the ultrasound + cfDNA analysis arm. There were no differences in maternal and gestational age, maternal weight and BMI, ethnicity, use of assisted reproduction and cigarette smoking between the two arms. In the ultrasound + cfDNA analysis arm, median risk for trisomy 21 was 1 in 10 000. None of the cases had a risk above 1: 100 (95% CI, 0.0-0.5%). In the FTCS arm, the median risk for trisomy 21 was 1 in 3787 and in 17 cases, the risk was higher than 1:100, which corresponds to 2.5% (95% CI, 1.5-3.9%) of the FTCS study-arm population. CONCLUSION Our study has shown that first-trimester risk assessment for trisomy 21 that includes a detailed ultrasound examination as well as NT measurement and is followed by cfDNA testing is associated with a significant reduction in the false-positive rate compared with FTCS. This approach obviates the need for maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A in screening for fetal aneuploidy. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- K O Kagan
- Department of Women's Health, University Women's Hospital Tuebingen, Tuebingen, Germany
| | - F Sroka
- Department of Women's Health, University Women's Hospital Tuebingen, Tuebingen, Germany
| | - J Sonek
- Fetal Medicine Foundation USA, Dayton, OH, USA
- Division of Maternal Fetal Medicine, Wright State University, Dayton, OH, USA
| | - H Abele
- Department of Women's Health, University Women's Hospital Tuebingen, Tuebingen, Germany
| | | | - M Schmid
- Roche Sequencing Solutions Inc., Ariosa Diagnostics Inc., San Jose, CA, USA
| | - P Wagner
- Department of Women's Health, University Women's Hospital Tuebingen, Tuebingen, Germany
| | - S Brucker
- Department of Women's Health, University Women's Hospital Tuebingen, Tuebingen, Germany
| | - D Wallwiener
- Department of Women's Health, University Women's Hospital Tuebingen, Tuebingen, Germany
| | - M Hoopmann
- Department of Women's Health, University Women's Hospital Tuebingen, Tuebingen, Germany
| |
Collapse
|
25
|
Krämer B, Neis F, Taran A, Schöller D, Isaacson K, Brucker S. Laparoscopic Radiofrequency Ablation (Lap-RFA) of Symptomatic Myomas and Laparoscopic Myomectomy (LM): Long-Term Outcomes From a Randomized Trial of Uterine-Sparing Techniques. J Minim Invasive Gynecol 2017. [DOI: 10.1016/j.jmig.2017.08.452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Mat Husin H, Schleger F, Kiefer-Schmidt I, Weiss M, Fehlert E, Kagan KO, Brucker S, Fritsche A, Preissl H. Maternal metabolism in the fasting state and fetal cardiac activity. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- H Mat Husin
- fMEG Centre, University of Tübingen, Tübingen, Germany
| | - F Schleger
- Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany
| | - I Kiefer-Schmidt
- Department of Obstetrics and Gynaecology, University Hospital, Eberhard Karls University, Tübingen, Germany
| | - M Weiss
- Department of Obstetrics and Gynaecology, University Hospital, Eberhard Karls University, Tübingen, Germany
| | - E Fehlert
- Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany
| | - KO Kagan
- Eberhard Karls Universität Tübingen, Department of Obstetrics and Gynaecology, University Hospital, Tübingen, Germany
| | - S Brucker
- Department of Obstetrics and Gynaecology, University Hospital, Eberhard Karls University, Tübingen, Germany
| | - A Fritsche
- Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany
| | - H Preissl
- Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany
| |
Collapse
|
27
|
Weiss M, Daeschlein G, Kramer A, Burchardt M, Brucker S, Wallwiener D, Stope MB. Virucide properties of cold atmospheric plasma for future clinical applications. J Med Virol 2017; 89:952-959. [DOI: 10.1002/jmv.24701] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/26/2016] [Indexed: 12/30/2022]
Affiliation(s)
- M. Weiss
- Department of Gynecology and Obstetrics; University Medicine Tübingen; Tübingen Germany
- Department of Urology; University Medicine Greifswald; Greifswald Germany
| | - G. Daeschlein
- Department of Dermatology; University Medicine Greifswald; Greifswald Germany
| | - A. Kramer
- Department of Hygiene and Environmental Medicine; University Medicine Greifswald; Greifswald Germany
| | - M. Burchardt
- Department of Urology; University Medicine Greifswald; Greifswald Germany
| | - S. Brucker
- Department of Gynecology and Obstetrics; University Medicine Tübingen; Tübingen Germany
| | - D. Wallwiener
- Department of Gynecology and Obstetrics; University Medicine Tübingen; Tübingen Germany
| | - M. B. Stope
- Department of Urology; University Medicine Greifswald; Greifswald Germany
| |
Collapse
|
28
|
Fehlert E, Willmann K, Fritsche L, Linder K, Mat-Husin H, Schleger F, Weiss M, Kiefer-Schmidt I, Brucker S, Häring HU, Preissl H, Fritsche A. Gestational diabetes alters the fetal heart rate variability during an oral glucose tolerance test: a fetal magnetocardiography study. BJOG 2016; 124:1891-1898. [PMID: 28029217 DOI: 10.1111/1471-0528.14474] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/03/2016] [Indexed: 12/20/2022]
Abstract
OBJECTIVE Gestational diabetes mellitus (GDM) potentially harms the child before birth. We previously found GDM to be associated with developmental changes in the central nervous system. We now hypothesise that GDM may also impact on the fetal autonomic nervous system under metabolic stress like an oral glucose tolerance test (OGTT). DESIGN We measured heart rate variability (HRV) of mothers and fetuses during a three-point OGTT using fetal magnetocardiography (fMCG). SETTING Measurements were performed in the fMEG Centre in Tübingen. POPULATION After exclusion of 23 participants, 13 pregnant women with GDM and 36 pregnant women with normal glucose tolerance were examined. METHODS All women underwent the same examination setting with OGTT during which fMCG was recorded three times. MAIN OUTCOME MEASURE(S) Parameters of heart rate variability were measured. RESULTS Compared with mothers with normal glucose regulation, mothers with GDM showed increased heart rate but no significant differences of maternal HRV. In contrast, HRV in fetuses of mothers with GDM differed from those in the metabolically healthy group regarding standard deviation normal to normal beat (SDNN) (P = 0.012), low-frequency band (P = 0.008) and high-frequency band (P = 0.031). These HRV parameters exhibit a decrease only in GDM fetuses during the second hour of the OGTT. CONCLUSIONS These results show an altered response of the fetal autonomic nervous system to metabolic stress in GDM-complicated pregnancies. Hence, disturbances in maternal glucose metabolism might not only impact on the central nervous system of the fetus but may also affect the fetal autonomic nervous system. TWEETABLE ABSTRACT Metabolic stress reveals a different response of fetal autonomic nervous system in GDM-complicated pregnancies.
Collapse
Affiliation(s)
- E Fehlert
- Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Department of Internal Medicine, University Hospital, Eberhard Karls University, Tübingen, Germany.,Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany.,German Centre for Diabetes Research (DZD), Tübingen, Germany
| | - K Willmann
- Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Department of Internal Medicine, University Hospital, Eberhard Karls University, Tübingen, Germany
| | - L Fritsche
- Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Department of Internal Medicine, University Hospital, Eberhard Karls University, Tübingen, Germany.,Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany.,German Centre for Diabetes Research (DZD), Tübingen, Germany
| | - K Linder
- Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Department of Internal Medicine, University Hospital, Eberhard Karls University, Tübingen, Germany.,Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany.,German Centre for Diabetes Research (DZD), Tübingen, Germany
| | - H Mat-Husin
- Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Department of Internal Medicine, University Hospital, Eberhard Karls University, Tübingen, Germany
| | - F Schleger
- Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany.,German Centre for Diabetes Research (DZD), Tübingen, Germany
| | - M Weiss
- Department of Obstetrics and Gynaecology, University Hospital, Eberhard Karls University, Tübingen, Germany
| | - I Kiefer-Schmidt
- Department of Obstetrics and Gynaecology, University Hospital, Eberhard Karls University, Tübingen, Germany
| | - S Brucker
- Department of Obstetrics and Gynaecology, University Hospital, Eberhard Karls University, Tübingen, Germany
| | - H-U Häring
- Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Department of Internal Medicine, University Hospital, Eberhard Karls University, Tübingen, Germany.,Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany.,German Centre for Diabetes Research (DZD), Tübingen, Germany
| | - H Preissl
- Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Department of Internal Medicine, University Hospital, Eberhard Karls University, Tübingen, Germany.,Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany.,German Centre for Diabetes Research (DZD), Tübingen, Germany.,Department of Pharmacy and Biochemistry, Institute of Pharmaceutical Sciences, Tübingen, Germany.,Interfaculty Centre for Pharmacogenomics and Pharma Research, Eberhard Karls Universität Tübingen, Tübingen, Germany.,Institute for Diabetes and Obesity, Helmholtz Diabetes Centre, Helmholtz Zentrum München, German Research Centre for Environmental Health (GmbH), Neuherberg, Germany
| | - A Fritsche
- Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Department of Internal Medicine, University Hospital, Eberhard Karls University, Tübingen, Germany.,Institute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, University of Tübingen, Tübingen, Germany.,German Centre for Diabetes Research (DZD), Tübingen, Germany
| |
Collapse
|
29
|
Isaacson KB, Krämer B, Taran A, Kraemer D, Brucker S, Hahn M. Laparoscopic Radiofrequency Volumetric Thermal Ablation (RFVTA) of Symptomatic Myomas and Laparoscopic Myomectomy (LM): Clinical Outcomes at Three Years from a Randomized Trial of Uterine-Sparing Techniques. J Minim Invasive Gynecol 2016. [DOI: 10.1016/j.jmig.2016.08.102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Henes M, Huebner S, Taran FA, Brucker S, Henes J, Rall K. Einfluss auf die ovarielle Reserve bei Patientinnen mit autoinflammatorischen Erkrankungen, Evaluation anhand des Anti-Müller-Hormons. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
31
|
Krämer B, Neis F, Kraemer D, Brucker S. Die SONATA Studie: Ultraschallgesteuerte, transzerviakle Radiofrequenzablation von Myomen. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Keul J, Taran A, Kommoss F, Hartkopf A, Wallwiener D, Brucker S, Oberlechner E, Staebler A, Kommoss S. Maligne Keimzell- und Keimstrang-Stromatumoren des Ovars: Systematische Erfassung und Durchführung einer spezialisierten histopathologischen Zweitbegutachtung. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
33
|
Hartkopf A, Fehm T, Hahn M, Walter C, Wallwiener M, Taran FA, Brucker S. Nachweis disseminierter Tumorzellen im Knochenmark von Männern mit Mammakarzinom im Frühstadium. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
34
|
Wagner P, Kommoss S, Hartkopf A, Neis F, Abele H, Krämer B, Reisenauer C, Wallwiener D, Brucker S, Taran FA. Das präoperativ nicht erkannte Endometriumkarzinom: Häufigkeit und Charakteristika nach Hysterektomie aus benigner Indikation. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
35
|
Hübner S, Lenz M, Brucker S, Wallwiener D, Rall K, Henes M. Kann anhand des AMH-Wertes eine Vorhersage zur Fertilisierungsrate bei IVF-bzw. ICSI-Therapie getroffen werden? Eine retrospektive Analyse am Kinderwunschzentrum der Universitätsfrauenklinik Tübingen. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
36
|
Wallwiener S, Müller M, Brucker S, Reck C, Pauluschke-Fröhlich J, Götz M, Stolpner I, Sohn C, Abele H, Wallwiener M. Von ePregnancy zu Prelax: Von der Analyse der Anwenderinnen von Schwangerschaftsapplikationen hin zur Analyse der Compliance und des Benefits. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593233] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
37
|
Kommoss F, Grevenkamp F, Taran FA, Fend F, Brucker S, Wallwiener D, Schönfisch B, Lax S, Kommoss F, Staebler A, Kommoss S. L1CAM als wichtiger Prognosefaktor für Endometriumkarzinome mit niedrigem/intermediärem Risikoprofil. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
38
|
Engler T, Rall K, Taran AF, Brucker S, Hartkopf A, Henes M. Der Einfluss einer Zystenentfernung an den Adnexen auf die ovarielle Reserve erhoben anhand des Anti-Müller Hormons – Abhängigkeit von Histologie, Größe und Operationsart. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
39
|
Hartkopf A, Fehm T, Hahn M, Gruber I, Wallwiener M, Tarab FA, Brucker S. Disseminierte Tumorzellen zur Überwachung der adjuvanten Therapie bei Patientinnen mit Mammakarzinom im Frühstadium. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
40
|
Bosse K, Jordan L, Gruber I, Hartkopf A, Helms G, Röhm C, Grischke EM, Hahn M, Brucker S, Wallwiener D, Oberlechner E. Häufigkeit der „erblichen Belastung für Brust- und Eierstockkrebs“ bei Patientinnen mit Mammakarzinom am Brustzentrum der Universitätsfrauenklinik Tübingen. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
41
|
Grevenkamp F, Kommoss FKF, Kommoss FGM, Lax S, Fend F, Wallwiener D, Schönfisch B, Krämer B, Brucker S, Taran FA, Staebler A, Kommoss S. Stellenwert einer spezialisierten gynäkopathologischen Zweitbegutachtung in der Behandlung des Endometriumkarzinoms. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
42
|
Fasching PA, Lux MP, Häberle L, Wallwiener M, Schneeweiss A, Tesch H, Belleville E, Spall T, Müller V, Brucker S, Lück HJ. SERAPHINA – Safety, Efficacy and patient Reported outcomes of Advanced breast cancer Patients: tHerapy management wIth NAb-paclitaxel in daily routine (a non-interventional study). Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
43
|
Weiss M, Stope MB, Klinkmann G, Könsgen D, Brucker S, Wallwiener D, Burchardt M, Mustea A. Induction and secretion of pro-oncogenic heat shock protein 27 in ovarian cancer cells. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
44
|
Wolz-Beck M, Reisenauer C, Hahn S, Brucker S, Hübner M. Physio- und Verhaltenstherapie zur Behandlung der Überaktiven Blase (OAB). Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
45
|
Doster A, Plewniok K, Müller M, Feller S, Brucker S, Reck C, Wallwiener M, Wallwiener C, Wallwiener S. Prävalenz und Risikofaktoren für sexuelle Dysfunktion in Schwangerschaft und Wochenbett Ergebnisse einer prospektiven Längsschnittstudie in Deutschland. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
46
|
Gaß P, Fasching PA, Beckmann MW, Blum S, Brucker S, Taran FA, Schneeweiss A, Wallwiener M. Evaluation einer elektronischen Erhebung von Patient-reported-Outcomes (PROs) in der PRAEGNANT Studie. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
47
|
Kern C, Wallwiener D, Brucker S, Hübner S, Henes M. Steigende Schwangerschaftsraten nach Blastozysten-Transfer als gute Möglichkeit für Patienten mit wiederholtem IVF/ICSI-Versuch. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
48
|
Kaufmann AK, Vogel U, Meisner C, Krainick-Strobel U, Hattermann V, Wiesinger B, Wallwiener D, Helms G, Röhm C, Brucker S, Hahn M. Stellenwert bildgebender Verfahren zur Responsekontrolle unter Neoadjuvanter Chemotherapie. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
49
|
Spall T, Fasching PA, Häberle L, Becker S, Fehm T, Schneeweiss A, Tesch H, Brucker S, Belleville E. PerFECT-Pertuzumab in First-Line Treatment of HER2-positive metastatic breast Cancer patients: A cohort-study of patients treated either with docetaxel and Trastuzumab or docetaxel, trastuzumab and pertuzumab. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
50
|
Liaci ALS, Stäbler A, Hübner M, Brucker S, Reisenauer C. Diagnostik und Management von paravaginalen benignen Raumforderungen am Beispiel von 69 Fällen. Was sollte ein (Uro) Gynäkologe wissen? Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|